DRTG released its 2024 annual performance, with a net profit attributable to the parent company of 2.229 billion yuan, a year-on-year increase of 125.94%

According to the Zhitong Finance APP, TJ DaRenTang (600329.SH) released its annual report for 2024, reporting an operating income of 7.307 billion yuan, a year-on-year decrease of 11.14%; net profit attributable to shareholders of the listed company was 2.229 billion yuan, a year-on-year increase of 125.94%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 746 million yuan, a year-on-year decrease of 21.62%; basic earnings per share were 2.90 yuan/share. It is proposed to distribute a cash dividend of 12.80 yuan (including tax) for every 10 shares. The company has formed a group of traditional Chinese medicine production enterprises in the pharmaceutical manufacturing field, with DaRenTang, LongShunRong, LeRenTang, LiuZhongYao, and JingWanHong as the core of intelligent manufacturing, and companies producing medicinal materials and traditional Chinese medicine pieces as the front-end medicinal material resource centers. The products include a multi-series product group known as "Three Cores and Nine Wings." Well-known products include SuXiaoJiuXinWan, QingYanDiWan, JingWanHong Ointment, AnGongNiuHuangWan, QingFeiXiaoYanWan, QingGongShouTaoWan, BiQiJiaoNang, NiuHuangQingXinWan, TongMaiYangXinWan, and WeiChangAnWan. During the reporting period, the company used the entire equity of its wholly-owned subsidiary Tianjin Zhongxin Pharmaceutical Co., Ltd. to increase its capital in JinYao TaiPing Pharmaceutical Co., Ltd. After the capital increase is completed, the commercial business assets held by the company will be reflected in its 43.35% equity in JinYao TaiPing Pharmaceutical Co., Ltd., which is an associate company. The company will no longer recognize the revenue from this business asset in its consolidated financial statements, but will recognize profits and losses according to its equity ratio